Asuragen to Present at 2018 ACMG Annual Clinical Genetics Meeting

Austin, Texas — 4/03/2018 — Asuragen, Inc., a molecular diagnostics company delivering easy to use products for complex testing in genetics and oncology, will highlight several of its new products launching this year at the upcoming ACMG Annual Clinical Genetics Meeting on April 10-14 in Charlotte, North Carolina.

“We continue to demonstrate the value of our unique chemistries by making products available for challenging genetic targets, including the DMPK, SMN1 and HTT genes implicated in myotonic dystrophy, spinal muscular atrophy, and Huntington’s disease” said Matthew McManus, M.D., Ph.D., president and CEO of Asuragen. “By extending the workflow and performance benefits of our AmplideX® technology to these three gene targets, we aim to transform how these targets are characterized and make assays that are simple, accurate and accessible to laboratories everywhere.”

Asuragen’s posters will be presented concurrently during the poster session on Thursday, April 12, from 10:00 – 11:30 a.m.

Poster 377:
A Rapid, High-throughput PCR Fragment-sizing Assay for Quantifying Spinal Muscular Atrophy (SMN1, SMN2) Copy Numbers (Stela Filipovic-Sadic)

 Poster 439:
Robust PCR/CE Assay Using AmplideX Technology for Rapid and Accurate Genotyping of CAG Repeat Expansions in HTT (Julie Thibert)

The company will also have a presence at booth #1402 during the conference.

* Products currently in development. For research use only. Not for use in diagnostic procedures.

About Asuragen
Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach.  Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit

Lynne Hohlfeld
SVP, Corporate Development & CFO
Asuragen, Inc.

Asuragen, Inc.
2150 Woodward St., Suite 100
Austin, TX 78744
PH: 512.681.5200
T: 877.777.1874
F: 512.681.5201


Back To